Constellium Q3 2026 net income rises to $119M
Higher metal prices lifted revenue per ton, while total shipment volume declined 1% year over year.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Constellium SE reported third-quarter 2026 revenue of $2.639 billion, up from $2.166 billion a year earlier, while net income was $119 million versus $88 million. Revenue per ton increased, including from higher metal prices, but shipments slipped 1% to 368,000 metric tons. Basic earnings per share were $0.87, compared with $0.63.
For the first nine months, revenue was $7.848 billion versus $6.248 billion and net income was $463 million versus $162 million. Segment Adjusted EBITDA for the quarter was $280 million, compared with $196 million; P&ARP rose to $162 million from $82 million, while AS&I fell to $21 million from $33 million. Operating cash flow was $420 million, compared with $271 million. At September 30, 2026, total liquidity was $992 million. The company repurchased 2.8 million ordinary shares for $78 million and redeemed $100 million of its 5.625% Senior Notes due June 2028. On October 22, 2026, the Pan-U.S. ABL amendment increased available commitments from $550 million to $700 million and extended maturity to October 22, 2031.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointThird-quarter revenue was $2.639 billion, versus $2.166 billion a year earlier.
- Moderate pointThird-quarter net income was $119 million, versus $88 million a year earlier.
- Moderate pointSegment Adjusted EBITDA reached $280 million, versus $196 million.
Negative
- Moderate pointAS&I third-quarter Segment Adjusted EBITDA fell to $21 million from $33 million.
Filing Explained
The company reports that its board approved cancellation of 6 million treasury shares, and the equity statement records the cancellation by
Key Figures
Key Terms
Segment Adjusted EBITDA financial
metal price lag financial
accounts receivable factoring programs financial
cash flow hedges financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did CSTM report in the third quarter of 2026?
How much net income did CSTM report in the third quarter of 2026?
Why did Constellium's P&ARP Segment Adjusted EBITDA increase?
What drove CSTM's operating cash flow in the first nine months of 2026?
AI-generated analysis. How Rhea-AI works. Not financial advice.
(Mark One) | |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |||||
300 East Lombard Street, Suite 1710 | ||||||
(Zip Code) | ||||||
(Address of principal executive office (US)) | ||||||
(Registrant's telephone number, including area code) | ||||||
Securities registered pursuant to section 12(b) of the Act | ||||||
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||
☑ | Accelerated filer | ☐ | ||
Non-accelerated filer | ☐ | Smaller reporting company | ||
Emerging growth company |
Page | |||
PART 1 | |||
Item 1. | Financial Statements | 1 | |
Consolidated Income Statements (unaudited) | 1 | ||
Consolidated Statements of Comprehensive Income (unaudited) | 2 | ||
Consolidated Balance Sheets (unaudited) | 3 | ||
Consolidated Statements of Changes in Equity (unaudited) | 4 | ||
Consolidated Statements of Cash Flows (unaudited) | 6 | ||
Notes to the Unaudited Interim Condensed Consolidated Financial Statements | 7 | ||
Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 26 | |
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 38 | |
Item 4. | Controls and Procedures | 38 | |
PART II | |||
Item 1. | Legal Proceedings | 39 | |
Item 1A. | Risk Factors | 39 | |
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 39 | |
Item 3. | Defaults Upon Senior Securities | 39 | |
Item 4. | Mine Safety Disclosures | 39 | |
Item 5. | Other Information | 39 | |
Item 6. | Exhibits | 40 | |
SIGNATURES | 41 | ||
Three months ended September 30, | Nine months ended September 30, | |||||||||
(in millions of U.S. dollars) | Notes | 2026 | 2025 | 2026 | 2025 | |||||
Revenue | 2 | |||||||||
Cost of sales (excluding depreciation and amortization) | ( | ( | ( | ( | ||||||
Depreciation and amortization | ( | ( | ( | ( | ||||||
Selling and administrative expenses | ( | ( | ( | ( | ||||||
Research and development expenses | ( | ( | ( | ( | ||||||
Other gains and losses – net | 4 | ( | ||||||||
Finance costs – net | 5 | ( | ( | ( | ( | |||||
Income before tax | ||||||||||
Income tax expense | 6 | ( | ( | ( | ( | |||||
Net income | ||||||||||
Attributable to: | ||||||||||
Equity holders of Constellium SE | ||||||||||
Non-controlling interests | ||||||||||
Net income | ||||||||||
Earnings per share attributable to the equity holders of Constellium SE (in U.S. dollars) | Notes | |||||||||
Basic | 7 | |||||||||
Diluted | 7 |
Three months ended September 30, | Nine months ended September 30, | |||||||||
(in millions of U.S. dollars) | Notes | 2026 | 2025 | 2026 | 2025 | |||||
Net income | ||||||||||
Other comprehensive (loss) / income | ||||||||||
Net change in post-employment benefit obligations | ( | ( | ( | ( | ||||||
Income tax on net change in post- employment benefit obligations | ||||||||||
Net change in cash flow hedges | 12 | ( | ( | ( | ||||||
Income tax on cash flow hedges | ( | |||||||||
Currency translation adjustments | ( | ( | ||||||||
Other comprehensive (loss) / income | ( | ( | ( | |||||||
Total comprehensive income | ||||||||||
Attributable to: | ||||||||||
Equity holders of Constellium SE | ||||||||||
Non-controlling interests | ||||||||||
Total comprehensive income | ||||||||||
(in millions of U.S. dollars) except share data and as otherwise stated | Notes | At September 30, 2026 | At December 31, 2025 | |||
Assets | ||||||
Current assets | ||||||
Cash and cash equivalents | ||||||
Trade receivables and other, net | 8 | |||||
Inventories | 9 | |||||
Fair value of derivative instruments and other financial assets | 12 | |||||
Total current assets | ||||||
Non-current assets | ||||||
Property, plant and equipment, net | ||||||
Goodwill | ||||||
Intangible assets, net | ||||||
Deferred tax assets | ||||||
Trade receivables and other, net | 8 | |||||
Fair value of derivative instruments | 12 | |||||
Total non-current assets | ||||||
Total assets | ||||||
Liabilities | ||||||
Current liabilities | ||||||
Trade payables and other | 10 | |||||
Current portion of long-term debt | 11 | |||||
Fair value of derivative instruments | 12 | |||||
Income tax payable | ||||||
Pension and other benefit obligations | ||||||
Provisions | 14 | |||||
Total current liabilities | ||||||
Non-current liabilities | ||||||
Trade payables and other | 10 | |||||
Long-term debt | 11 | |||||
Fair value of derivative instruments | 12 | |||||
Pension and other benefit obligations | ||||||
Provisions | 14 | |||||
Deferred tax liabilities | ||||||
Total non-current liabilities | ||||||
Total liabilities | ||||||
Commitments and contingencies | 14 | |||||
Shareholders' equity | ||||||
Ordinary shares, par value € September 30, 2026 and at December 31, 2025, respectively; respectively | ||||||
Additional paid in capital | ||||||
Accumulated other comprehensive income | 15 | |||||
Retained earnings | ||||||
Treasury shares 2025 | ( | ( | ||||
Equity attributable to equity holders of Constellium SE | ||||||
Non-controlling interests | ||||||
Total equity | ||||||
Total equity and liabilities |
in millions of U.S. dollars, except share amounts | Ordinary shares outstanding | Ordinary shares | Treasury shares | Accumulated other comprehensive income / (loss) | Additional paid in capital | Retained earnings | Non- controlling interests | Total equity | ||||||||
At January 1, 2026 | ( | |||||||||||||||
Net income | — | — | — | — | — | ( | ||||||||||
Other comprehensive loss | — | — | — | ( | — | — | — | ( | ||||||||
Total comprehensive income | — | — | — | ( | — | ( | ||||||||||
Share-based compensation | — | — | — | — | — | — | ||||||||||
Repurchase of ordinary shares | ( | — | ( | — | — | — | — | ( | ||||||||
Allocation of treasury shares to share-based compensation plan vested | — | — | — | ( | — | |||||||||||
Transactions with non- controlling interests | — | — | — | — | — | — | ( | ( | ||||||||
At March 31, 2026 | ( | |||||||||||||||
Net income | — | — | — | — | — | |||||||||||
Other comprehensive loss | — | — | — | ( | — | — | — | ( | ||||||||
Total comprehensive income | — | — | — | ( | — | |||||||||||
Share-based compensation | — | — | — | — | — | — | ||||||||||
Repurchase of ordinary shares | ( | — | ( | — | — | — | — | ( | ||||||||
Other | — | — | — | — | ( | ( | ( | |||||||||
Transactions with non- controlling interests | — | — | — | — | — | — | ( | ( | ||||||||
At June 30, 2026 | ( | |||||||||||||||
Net income | — | — | — | — | — | |||||||||||
Other comprehensive loss | — | — | — | ( | — | — | — | ( | ||||||||
Total comprehensive (loss) / income | — | — | — | ( | — | |||||||||||
Share-based compensation | — | — | — | — | — | — | ||||||||||
Repurchase of ordinary shares | ( | — | ( | — | — | — | — | ( | ||||||||
Allocation of treasury shares to share-based compensation plan vested | — | — | — | — | — | — | ||||||||||
Cancellation of treasury shares | — | — | — | ( | — | — | ( | |||||||||
Transactions with non- controlling interests | — | — | — | — | — | — | ( | ( | ||||||||
At September 30, 2026 | ( | |||||||||||||||
in millions of U.S. dollars, except share amounts | Ordinary shares outstanding | Ordinary shares | Treasury shares | Accumulated other comprehensive income / (loss) | Additional paid in capital | Retained earnings | Non- controlling interests | Total equity | ||||||||
At January 1, 2025 | ( | ( | ||||||||||||||
Net income | — | — | — | — | — | |||||||||||
Other comprehensive loss | — | — | — | — | — | — | ||||||||||
Total comprehensive (loss) / income | — | — | — | — | ||||||||||||
Share-based compensation | — | — | — | — | — | — | ||||||||||
Repurchase of ordinary shares | ( | — | ( | — | — | — | — | ( | ||||||||
Allocation of treasury shares to share-based compensation plan vested | — | — | — | ( | — | |||||||||||
Other | — | — | — | — | ( | — | ||||||||||
Transactions with non- controlling interests | — | — | — | — | — | — | ( | ( | ||||||||
At March 31, 2025 | ( | ( | ||||||||||||||
Net income | — | — | — | — | — | — | ||||||||||
Other comprehensive loss | — | — | — | — | — | |||||||||||
Total comprehensive (loss) / income | — | — | — | — | ||||||||||||
Share-based compensation | — | — | — | — | — | — | ||||||||||
Repurchase of ordinary shares | ( | — | ( | — | — | — | — | ( | ||||||||
Transactions with non- controlling interests | — | — | — | — | — | — | ( | ( | ||||||||
At June 30, 2025 | ( | |||||||||||||||
Net income | — | — | — | — | — | — | ||||||||||
Other comprehensive income | — | — | — | ( | — | — | — | ( | ||||||||
Total comprehensive income | — | — | — | ( | — | |||||||||||
Share-based compensation | — | — | — | — | — | — | ||||||||||
Repurchase of ordinary shares | ( | — | ( | — | — | — | — | ( | ||||||||
Transactions with non- controlling interests | — | — | — | — | — | — | ( | ( | ||||||||
At September 30, 2025 | ( |
Nine months ended September 30, | ||||||
(in millions of U.S. dollars) | Notes | 2026 | 2025 | |||
Net income | ||||||
Adjustments | ||||||
Depreciation and amortization | 3 | |||||
Impairment of assets | 3 | |||||
Pension and other long-term benefits | ||||||
Finance costs - net | 5 | |||||
Income tax expense | ||||||
Unrealized (gains) /losses on derivatives - net and from remeasurement of monetary assets and liabilities - net | ( | |||||
Losses on disposal | 4 | |||||
Other - net | ||||||
Changes in working capital | ||||||
Inventories | ( | ( | ||||
Trade receivables | ( | ( | ||||
Trade payables | ||||||
Other | ( | |||||
Change in provisions | ( | ( | ||||
Pension and other long-term benefits paid | ( | ( | ||||
Interest paid | ( | ( | ||||
Income tax paid | ( | ( | ||||
Net cash flows from operating activities | ||||||
Purchases of property, plant and equipment | 3 | ( | ( | |||
Property, plant and equipment inflows | 3 | |||||
Collection of deferred purchase price receivable | 8 | |||||
Proceeds from disposals, net of cash | ||||||
Other investing activities | ||||||
Net cash flows used in investing activities | ( | ( | ||||
Repurchase of ordinary shares | ( | ( | ||||
Repayments of long-term debt | ( | ( | ||||
Net change in revolving credit facilities and short-term debt | ||||||
Finance lease repayments | ( | ( | ||||
Transactions with non-controlling interests | ( | ( | ||||
Other financing activities | ( | |||||
Net cash flows used in financing activities | ( | ( | ||||
Net (decrease) / increase in cash and cash equivalents | ( | |||||
Cash and cash equivalents - beginning of period | ||||||
Net (decrease) / increase in cash and cash equivalents | ( | |||||
Effect of exchange rate changes on cash and cash equivalents | ( | |||||
Cash and cash equivalents - end of period | ||||||
Three months ended September 30, | Nine months ended September 30, | |||||||
(in millions of U.S. dollars) | 2026 | 2025 | 2026 | 2025 | ||||
Aerospace rolled products | ||||||||
Transportation, industry, defense and other rolled products | ||||||||
Packaging rolled products | ||||||||
Automotive rolled products | ||||||||
Specialty and other thin-rolled products | ||||||||
Automotive extruded products | ||||||||
Other extruded products | ||||||||
Total revenue | ||||||||
Three months ended September 30, | ||||||||||
2026 | 2025 | |||||||||
(in millions of U.S. dollars) | A&T | P&ARP | AS&I | H&C (B) | A&T | P&ARP | AS&I | H&C (B) | ||
Segment revenue | ||||||||||
Inter-segment elimination | ( | ( | ( | ( | ( | ( | ||||
External revenue | ||||||||||
Cost of metal | ( | ( | ( | ( | ( | ( | ||||
Production costs | ( | ( | ( | ( | ( | ( | ( | ( | ||
Other segment expenses (A) | ( | ( | ( | ( | ( | ( | ( | ( | ||
Segment Adjusted EBITDA | ( | ( | ||||||||
Nine months ended September 30, | ||||||||||
2026 | 2025 | |||||||||
(in millions of U.S. dollars) | A&T | P&ARP | AS&I | H&C (B) | A&T | P&ARP | AS&I | H&C (B) | ||
Segment revenue | ||||||||||
Inter-segment elimination | ( | ( | ( | ( | ( | ( | ||||
External revenue | ||||||||||
Cost of metal | ( | ( | ( | ( | ( | ( | ||||
Production costs | ( | ( | ( | ( | ( | ( | ( | ( | ||
Other segment expenses (A) | ( | ( | ( | ( | ( | ( | ( | ( | ||
Segment Adjusted EBITDA | ( | ( | ||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||
(in millions of U.S. dollars) | Notes | 2026 | 2025 | 2026 | 2025 | |||||
A&T | ||||||||||
P&ARP | ||||||||||
AS&I | ||||||||||
H&C (A) | ( | ( | ( | ( | ||||||
Segment Adjusted EBITDA | ||||||||||
Metal price lag (B) | ( | |||||||||
Depreciation and amortization | ( | ( | ( | ( | ||||||
Impairment of assets | ( | |||||||||
Share based compensation | 16 | ( | ( | ( | ( | |||||
Pension and other post-employment benefits - non-operating gains | ||||||||||
Restructuring costs | ( | ( | ( | |||||||
Unrealized (losses) / gains on derivatives | ( | |||||||||
Unrealized exchange gains / (losses) from the remeasurement of monetary assets and liabilities – net | ||||||||||
Losses on disposal | ( | ( | ||||||||
Other (C) | ( | ( | ( | |||||||
Expenses on factoring arrangements | 8 | ( | ( | ( | ( | |||||
Finance costs – net | 5 | ( | ( | ( | ( | |||||
Income before tax | ||||||||||
Income tax expense | 6 | ( | ( | ( | ( | |||||
Net income | ||||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||
(in millions of U.S. dollars) | 2026 | 2025 | 2026 | 2025 | ||||
A&T | ( | ( | ( | ( | ||||
P&ARP | ( | ( | ( | ( | ||||
AS&I | ( | ( | ( | ( | ||||
H&C (A) | ( | ( | ( | ( | ||||
Total capital expenditures (B) | ( | ( | ( | ( | ||||
Three months ended September 30, | Nine months ended September 30, | |||||||
(in millions of U.S. dollars) | 2026 | 2025 | 2026 | 2025 | ||||
A&T | ( | ( | ( | ( | ||||
P&ARP | ( | ( | ( | ( | ||||
AS&I | ( | ( | ( | ( | ||||
H&C (A) | ( | ( | ( | ( | ||||
Total depreciation, amortization and impairment expense | ( | ( | ( | ( | ||||
(in millions of U.S. dollars) | At September 30, 2026 | At December 31, 2025 | ||
A&T | ||||
P&ARP | ||||
AS&I | ||||
H&C (A) | ||||
Deferred income tax assets | ||||
Cash and cash equivalents | ||||
Fair value of derivative instruments and other financial assets | ||||
Total assets |
Three months ended September 30, | Nine months ended September 30, | |||||||||
(in millions of U.S. dollars) | Notes | 2026 | 2025 | 2026 | 2025 | |||||
Operating income and expenses | ||||||||||
Realized gains / (losses) on derivatives (A) | ( | ( | ||||||||
Unrealized (losses) / gains on derivatives at fair value through profit and loss - net (A) | 12 | ( | ||||||||
Unrealized exchange gains / (losses) from the remeasurement of monetary assets and liabilities – net | ||||||||||
Impairment of assets | ( | |||||||||
Restructuring costs | ( | ( | ( | |||||||
Losses on disposal | ( | ( | ||||||||
Result from the flood in Valais | 3 | |||||||||
Non-operating income and expenses | ||||||||||
Expenses on factoring arrangements | 8 | ( | ( | ( | ( | |||||
Pension and other post-employment benefits | 13 | |||||||||
Other | ( | ( | ( | |||||||
Total other gains and losses - net | ( | |||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||
(in millions of U.S. dollars) | Notes | 2026 | 2025 | 2026 | 2025 | |||||
Interest expense on borrowings (A) | ( | ( | ( | ( | ||||||
Interest expense on finance leases | ( | ( | ||||||||
Interest cost on pension and other long-term benefits | 13 | ( | ( | ( | ( | |||||
Net loss on settlement of debt | ( | ( | ||||||||
Realized and unrealized (losses) / gains on debt derivatives at fair value (B) | 12 | ( | ||||||||
Realized and unrealized exchange gains / (losses) on financing activities - net (B) | ||||||||||
Other finance expenses | ( | ( | ( | ( | ||||||
Capitalized borrowing costs (C) | ||||||||||
Finance expenses | ( | ( | ( | ( | ||||||
Finance costs - net | ( | ( | ( | ( | ||||||
Three months ended September 30, | Nine months ended September 30, | |||||||
(in millions of U.S. dollars except share and per share amounts ) | 2026 | 2025 | 2026 | 2025 | ||||
Numerator: | ||||||||
Net income attributable to equity holders of Constellium SE | ||||||||
Denominator: | ||||||||
Basic - weighted-average ordinary shares outstanding | ||||||||
Dilutive effect of non-vested restricted stock units and performance-based restricted stock units | ||||||||
Diluted - weighted-average ordinary shares, of restricted stock units and performance-based restricted stock units | ||||||||
Basic earnings per share | $ | $ | $ | $ | ||||
Diluted earnings per share | $ | $ | $ | $ | ||||
At September 30, 2026 | At December 31, 2025 | |||
(in millions of U.S. dollars) | Current | Current | ||
Trade receivables - gross | ||||
Allowance for credit losses | ( | ( | ||
Total trade receivables - net | ||||
Total other receivables | ||||
Total trade receivables and other |
(in millions of U.S. dollars) | At September 30, 2026 | At December 31, 2025 | ||
Finished goods | ||||
Work in progress | ||||
Raw materials | ||||
Stores and supplies | ||||
Total inventories |
At September 30, 2026 | At December 31, 2025 | |||
(in millions of U.S. dollars) | Current | Current | ||
Trade payables | ||||
Employees' entitlements | ||||
Other payables | ||||
Total other | ||||
Total trade payables and other |
Nine months ended September 30, | ||||
(in millions of U.S. dollars) | 2026 | 2025 | ||
Contract liabilities and other liabilities to customers at January 1, | ||||
Revenue deferred to contract liabilities | ||||
Revenue recognized from contract liabilities | ( | ( | ||
Effect of changes in foreign currency rates and other changes | ( | |||
Contract liabilities and other liabilities to customers at September 30, | ||||
At September 30, 2026 | At December 31, 2025 | |||||||||
(in millions of U.S. dollars) | Nominal Value in Currency | Nominal rate | Effective rate | Face Value | Debt issuance costs | Accrued interest | Carrying value | Carrying value | ||
Secured Pan-U.S. ABL (due 2029) | $ | Floating | ||||||||
Senior Unsecured Notes | ||||||||||
Issued June 2020 and due 2028 (A) | $ | ( | ||||||||
Issued February 2021 and due 2029 | $ | ( | ||||||||
Issued June 2021 and due 2029 | € | ( | ||||||||
Issued August 2024 and due 2032 | $ | ( | ||||||||
Issued August 2024 and due 2032 | € | ( | ||||||||
Finance lease liabilities | ||||||||||
Other loans | ||||||||||
Total debt | ( | |||||||||
Of which non-current | ||||||||||
Of which current (B) | ||||||||||
At September 30, 2026 | At December 31, 2025 | |||||||||||
(in millions of U.S. dollars) | Non- current | Current | Total | Non- current | Current | Total | ||||||
Derivatives that qualify for hedge accounting | ||||||||||||
Currency commercial derivatives | ||||||||||||
Derivatives that do not qualify for hedge accounting | ||||||||||||
Currency commercial derivatives | ||||||||||||
Currency net debt derivatives | ||||||||||||
Energy derivatives | ||||||||||||
Metal derivatives | ||||||||||||
Fair value of derivative instruments - assets | ||||||||||||
Derivatives that qualify for hedge accounting | ||||||||||||
Currency commercial derivatives | ||||||||||||
Derivatives that do not qualify for hedge accounting | ||||||||||||
Currency commercial derivatives | ||||||||||||
Energy derivatives | ||||||||||||
Metal derivatives | ||||||||||||
Fair value of derivative instruments - liabilities | ||||||||||||
At September 30, 2026 | At December 31, 2025 | |||||||||||||||
(in millions of U.S. dollars) | Level 1 | Level 2 | Level 3 | Total | Level 1 | Level 2 | Level 3 | Total | ||||||||
Fair value of derivative instruments - assets | ||||||||||||||||
Fair value of derivative instruments - liabilities | ||||||||||||||||
Sold currencies | Maturity Year | Less than 1 year | Over 1 year | |||
USD | 2026-2031 | |||||
CHF | 2026-2031 | |||||
CZK | 2026 | |||||
Other currencies | 2026-2027 |
Purchased currencies | ||||||
USD | 2026-2028 | |||||
CHF | 2026-2030 | |||||
CZK | 2026-2028 | |||||
Other currencies | 2027 |
Three months ended September 30, | Nine months ended September 30, | |||||||
(in millions of U.S. dollars) | 2026 | 2025 | 2026 | 2025 | ||||
Derivatives that do not qualify for hedge accounting | ||||||||
Included in Other gains and losses - net | ||||||||
Realized (losses) / gains on foreign currency derivatives - net (A) | ( | ( | ||||||
Unrealized (losses) / gains on foreign currency derivatives - net (B) | ( | ( | ( | |||||
Derivatives that qualify for hedge accounting | ||||||||
Included in Other comprehensive income | ||||||||
Unrealized (losses) / gains on foreign currency derivatives - net | ( | ( | ( | |||||
(Losses) / gains reclassified from cash flow hedge reserve to the Consolidated Income Statement | ( | ( | ( | |||||
Included in Revenue (C) | ||||||||
Realized gains / (losses) on foreign currency derivatives - net (A) | ( | |||||||
Unrealized (losses) / gains on foreign currency derivatives - net | ( | |||||||
Three months ended September 30, | Nine months ended September 30, | |||||||
(in millions of U.S. dollars) | 2026 | 2025 | 2026 | 2025 | ||||
Derivatives that do not qualify for hedge accounting | ||||||||
Included in Finance costs - net | ||||||||
Realized gains / (losses) on foreign currency derivatives - net (A) | ( | |||||||
Unrealized gains / (losses) on foreign currency derivatives - net | ( | |||||||
Total | ( | |||||||
(in millions of U.S. dollars) | Maturity Year | Less than 1 year | Over 1 year | |||
Metal | 2026-2028 | |||||
Natural gas | 2026-2029 |
Three months ended September 30, | Nine months ended September 30, | |||||||
(in millions of U.S. dollar) | 2026 | 2025 | 2026 | 2025 | ||||
Derivatives that do not qualify for hedge accounting | ||||||||
Included in Other gains and losses - net | ||||||||
Realized gains / (losses) on commodities derivatives - net (A) | ( | |||||||
Unrealized gains / (losses) on commodities derivatives - net | ( | |||||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||
2026 | 2025 | 2026 | 2025 | ||||||||||
(in millions of U.S. dollars) | Pension | OPEB and Other Benefits | Pension | OPEB and Other Benefits | Pension | OPEB and Other Benefits | Pension | OPEB and Other Benefits | |||||
Current service cost | ( | ( | ( | ( | ( | ( | ( | ( | |||||
Interest cost | ( | ( | ( | ( | ( | ( | ( | ( | |||||
Expected return on plan assets | |||||||||||||
Immediate recognition of losses arising over the year | ( | ||||||||||||
Amortization of past service gain | |||||||||||||
Amortization of net actuarial gain | |||||||||||||
Curtailment and settlements | ( | ( | |||||||||||
Total net pension and other long- term benefit cost | ( | ( | ( | ( | ( | ||||||||
At September 30, 2026 | At December 31, 2025 | |||||||
(in millions of U.S. dollars) | Current | Non-current | Current | Non-current | ||||
Close down and environmental remediation costs | ||||||||
Restructuring costs | ||||||||
Legal claims and other costs | ||||||||
Total provisions | ||||||||
Three months ended September 30, 2026 | ||||||||
(in millions of U.S. dollars) | Post- employment benefit plans | Cash flow hedges | Currency translation adjustments | Accumulated other comprehensive income / (loss) | ||||
At June 30, 2026 | ( | |||||||
Other comprehensive income / (loss) before reclassification | ( | ( | ( | |||||
Amounts reclassified from accumulated other comprehensive income / (loss) to the income statement | ( | ( | ||||||
At September 30, 2026 | ( | ( | ||||||
Three months ended September 30, 2025 | ||||||||
(in millions of U.S. dollars) | Post- employment benefit plans | Cash flow hedges | Currency translation adjustments | Accumulated other comprehensive income / (loss) | ||||
At June 30, 2025 | ( | |||||||
Other comprehensive income / (loss) before reclassification | ( | ( | ( | |||||
Amounts reclassified from accumulated other comprehensive income / (loss) to the income statement | ( | ( | ( | |||||
At September 30, 2025 | ( | |||||||
Nine months ended September 30, 2026 | ||||||||
(in millions of U.S. dollars) | Post- employment benefit plans | Cash flow hedges | Currency translation adjustments | Accumulated other comprehensive income / (loss) | ||||
At January 1, 2026 | ( | |||||||
Other comprehensive income / (loss) before reclassification | ( | ( | ( | ( | ||||
Amounts reclassified from accumulated other comprehensive income / (loss) to the income statement | ( | ( | ( | |||||
Amounts reclassified from accumulated other comprehensive income / (loss) to retained earnings | ||||||||
At September 30, 2026 | ( | ( | ||||||
Nine months ended September 30, 2025 | ||||||||
(in millions of U.S. dollars) | Post- employment benefit plans | Cash flow hedges | Currency translation adjustments | Accumulated other comprehensive income / (loss) | ||||
At January 1, 2025 | ( | ( | ( | |||||
Other comprehensive income / (loss) before reclassification | ||||||||
Amounts reclassified from accumulated other comprehensive income / (loss) to the income statement | ( | ( | ( | |||||
Amounts reclassified from accumulated other comprehensive income / (loss) to retained earnings | ||||||||
At September 30, 2025 | ( | |||||||
2026 PSUs | ||
Fair value at grant date (in U.S. dollars) | ||
Share price at grant date (in U.S. dollars) | ||
Dividend yield | ||
Expected volatility (A) | ||
Risk-free interest rate (U.S. government bond yield) |
Three months ended September 30, 2026 | Nine months ended September 30, 2026 | |||||||
(as a % of total) | Revenue | Segment Adjusted EBITDA | Revenue | Segment Adjusted EBITDA | ||||
A&T | 25% | 36% | 25% | 40% | ||||
P&ARP | 62% | 58% | 61% | 56% | ||||
AS&I | 15% | 8% | 16% | 8% | ||||
H&C (1) | —% | (2)% | —% | (4)% | ||||
Total | 100% | 100% | 100% | 100% | ||||
Three months ended September 30, | Nine months ended September 30, | Percent changes QTD | Percent changes YTD | |||||||||
(U.S. dollars per ton) | 2026 | 2025 | 2026 | 2025 | 2026 vs 2025 | 2026 vs 2025 | ||||||
Average LME transaction price | 3,226 | 2,618 | 3,328 | 2,566 | 23% | 30% | ||||||
Average Midwest premium | 2,418 | 1,566 | 2,409 | 1,095 | 54% | 120% | ||||||
Average all-in aluminum price U.S. | 5,644 | 4,184 | 5,737 | 3,661 | 35% | 57% | ||||||
Average LME transaction price | 3,226 | 2,618 | 3,328 | 2,566 | 23% | 30% | ||||||
Average Rotterdam premium | 510 | 212 | 494 | 233 | 141% | 112% | ||||||
Average all-in aluminum price Europe | 3,736 | 2,830 | 3,822 | 2,799 | 32% | 37% | ||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
(in millions of U.S. dollars and as a % of revenue) | 2026 | 2025 | 2026 | 2025 | ||||||||||||
Revenue | 2,639 | 100% | 2,166 | 100% | 7,848 | 100% | 6,248 | 100% | ||||||||
Cost of sales (excluding depreciation and amortization) | (2,272) | 86% | (1,852) | 86% | (6,581) | 84% | (5,408) | 87% | ||||||||
Depreciation and amortization | (82) | 3% | (84) | 4% | (249) | 3% | (244) | 4% | ||||||||
Selling and administrative expenses | (84) | 3% | (85) | 4% | (282) | 4% | (251) | 4% | ||||||||
Research and development expenses | (12) | —% | (12) | 1% | (39) | —% | (37) | 1% | ||||||||
Other gains and losses – net | (2) | —% | 20 | 1% | 32 | —% | 19 | —% | ||||||||
Finance costs – net | (27) | 1% | (27) | 1% | (83) | 1% | (83) | 1% | ||||||||
Income before tax | 160 | 6% | 126 | 6% | 646 | 8% | 244 | 4% | ||||||||
Income tax expense | (41) | 2% | (38) | 2% | (183) | 2% | (82) | 1% | ||||||||
Net income | 119 | 5% | 88 | 4% | 463 | 6% | 162 | 3% | ||||||||
Shipment volumes (in kt) | 368 | n/a | 373 | n/a | 1,120 | n/a | 1,130 | n/a | ||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||
(in millions of U.S. dollars) | 2026 | 2025 | 2026 | 2025 | ||||
Realized (losses) / gains on foreign currency derivatives - net | (3) | 6 | (3) | 6 | ||||
Realized gains / (losses) on commodities derivatives - net | — | 4 | 104 | (15) | ||||
Realized (losses) / gains on derivatives | (3) | 10 | 101 | (9) | ||||
Unrealized (losses) / gains on foreign currency derivatives - net | (5) | (6) | (19) | 32 | ||||
Unrealized gains / (losses) on commodities derivatives - net | 10 | 19 | (36) | 2 | ||||
Unrealized gains / (losses) on derivatives at fair value through profit and loss - net | 5 | 13 | (55) | 34 | ||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
(in millions of U.S. dollars and as a % of revenue) | 2026 | 2025 | 2026 | 2025 | ||||||||||||
A&T | 664 | 25% | 481 | 22% | 1,954 | 25% | 1,441 | 23% | ||||||||
P&ARP | 1,625 | 62% | 1,307 | 60% | 4,782 | 61% | 3,729 | 60% | ||||||||
AS&I | 402 | 15% | 409 | 19% | 1,275 | 16% | 1,211 | 19% | ||||||||
H&C (1) | 2 | —% | 1 | —% | 6 | —% | 3 | —% | ||||||||
Inter-segment eliminations | (55) | n.m | (32) | n.m | (169) | n.m | (136) | n.m | ||||||||
Total revenue | 2,639 | 100% | 2,166 | 100% | 7,848 | 100% | 6,248 | 100% | ||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
(in kt and as a % of shipments) | 2026 | 2025 | 2026 | 2025 | ||||||||||||
A&T | 59 | 16% | 50 | 13% | 184 | 16% | 154 | 14% | ||||||||
P&ARP | 266 | 72% | 275 | 74% | 793 | 71% | 820 | 73% | ||||||||
AS&I | 46 | 13% | 48 | 13% | 151 | 14% | 155 | 14% | ||||||||
Inter-segment eliminations | (3) | n.m | — | n.m | (9) | n.m | (1) | n.m | ||||||||
Total shipments | 368 | 100% | 373 | 100% | 1,120 | 100% | 1,130 | 100% | ||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
(in millions of U.S. dollars and as a % of revenue) | 2026 | 2025 | 2026 | 2025 | ||||||||||||
A&T | 102 | 15% | 90 | 19% | 340 | 17% | 256 | 18% | ||||||||
P&ARP | 162 | 10% | 82 | 6% | 478 | 10% | 217 | 6% | ||||||||
AS&I | 21 | 5% | 33 | 8% | 71 | 6% | 67 | 6% | ||||||||
(in millions of U.S. dollars) | A&T | P&ARP | AS&I | |||
Segment Adjusted EBITDA for the three months ended September 30, 2025 | 90 | 82 | 33 | |||
Volume | 34 | (7) | (6) | |||
Price and product mix | 20 | 18 | (23) | |||
Costs | (40) | 70 | 18 | |||
Foreign exchange and other | (2) | (1) | (1) | |||
Segment Adjusted EBITDA for the three months ended September 30, 2026 | 102 | 162 | 21 | |||
(in millions of U.S. dollars) | A&T | P&ARP | AS&I | |||
Segment Adjusted EBITDA for the nine months ended September 30, 2025 | 256 | 217 | 67 | |||
Volume | 106 | (18) | (10) | |||
Price and product mix | 35 | 64 | (31) | |||
Costs | (64) | 208 | 42 | |||
Foreign exchange and other | 7 | 7 | 3 | |||
Segment Adjusted EBITDA for the nine months ended September 30, 2026 | 340 | 478 | 71 |
Nine months ended September 30, | ||||
(in millions of U.S. dollars) | 2026 | 2025 | ||
Net Cash Flows from / (used in) | ||||
Operating activities | 420 | 271 | ||
Investing activities | (195) | (200) | ||
Financing activities | (184) | (103) | ||
Net increase / (decrease) in cash and cash equivalents, excluding the effect of exchange rate changes | 41 | (32) | ||
Three months ended September 30, | Nine months ended September 30, | |||||||
(in millions of U.S. dollars) | 2026 | 2025 | 2026 | 2025 | ||||
Net income | 119 | 88 | 463 | 162 | ||||
Income tax expense | 41 | 38 | 183 | 82 | ||||
Finance costs – net | 27 | 27 | 83 | 83 | ||||
Expenses on factoring arrangements | 6 | 5 | 15 | 16 | ||||
Depreciation and amortization | 82 | 84 | 249 | 244 | ||||
Impairment of assets | — | — | 3 | — | ||||
Restructuring costs | — | 1 | 5 | 3 | ||||
Unrealized gains / (losses) on derivatives | (5) | (13) | 55 | (34) | ||||
Unrealized exchange gains from the remeasurement of monetary assets and liabilities – net | — | (1) | (1) | (1) | ||||
Pension and other post-employment benefits - non- operating gains | (3) | (3) | (10) | (10) | ||||
Share based compensation | 8 | 7 | 27 | 20 | ||||
Losses on disposal | — | — | 1 | 1 | ||||
Other (A) | 1 | 2 | 1 | — | ||||
Adjusted EBITDA1 | 276 | 235 | 1,074 | 566 | ||||
of which Metal price lag (B) | (4) | 39 | 222 | 59 | ||||
Period | Total number of shares purchased | Average price paid per share (in U.S. dollars) | Total number of shares purchased as part of publicly announced plans or programs(1) | Maximum approximate dollar value of shares that may yet be purchased under the program(2) | ||||
July 1 - July 31, 2026 | 515,106 | 29.12 | 515,106 | 272,000,049 | ||||
August 1 - August 31, 2026 | 529,335 | 28.34 | 529,335 | 257,000,065 | ||||
September 1 - September 30, 2026 | — | — | — | 257,000,065 | ||||
Total | 1,044,441 | 1,044,441 | 257,000,065 |
Exhibit | Description |
3.1 | Articles of Association of Constellium SE dated September 17, 2026** |
10.1 | Amendment No. 8 to Amended and Restated Credit Agreement, by and among Constellium Muscle Shoals LLC, Constellium Rolled Products Ravenswood, LLC, Constellium Bowling Green LLC, Constellium Holdings Muscle Shoals LLC, Constellium US Holdings I, LLC, Constellium US Intermediate Holdings LLC, the lenders signatory thereto, and Wells Fargo Bank, National Association, as Administrative Agent and Collateral Agent, dated as of October 22, 2026** |
31.1 | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002** |
31.2 | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002** |
32.1 | Certification by Chief Executive Officer of Constellium SE, as required pursuant to Section 906 of the Sarbanes-Oxley Act of 2002* |
32.2 | Certification by Chief Financial Officer of Constellium SE, as required pursuant to Section 906 of the Sarbanes-Oxley Act of 2002* |
101.INS | Inline XBRL Instance Document** |
101.SCH | Inline XBRL Taxonomy Extension Schema Document** |
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document** |
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document** |
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document** |
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document** |
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)** |
Constellium SE | |||
Date: | October 28, 2026 | By: | /s/ Ingrid Joerg |
Name: Ingrid Joerg | |||
Title: Chief Executive Officer and Director | |||
Date: | October 28, 2026 | By: | /s/ Jack Guo |
Name: Jack Guo | |||
Title: Executive Vice President & Chief Financial Officer |